Dendreon said today in its quarterly report that it finished the month of September with $106 million in cash and investments in the bank. The Seattle biotech company (NASDAQ: [[ticker:DNDN]]) said its net loss in the quarter was $26.8 million. It expects to get final clinical results from a trial of its leading prostate cancer drug candidate, Provenge, by the middle of 2009.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
